Several studies have suggested that OCT3 levels (SLC22A3) are reduced in intestinal tumors [32,33], which may be involved in the lack of response found in clinical practice in the treatment of other digestive tumors using irinotecan, cisplatin, and several TKIs, such as imatinib [37,38]. Here, SLC22A3 is linked to intestinal neoplasm.